BACKGROUND: Loss to follow-up (LTFU) in HIV-positive cohorts is an important surrogate for interrupted clinical care, which can potentially influence the assessment of HIV disease status and outcomes. After preliminary evaluation of LTFU rates and patient characteristics, we evaluated the risk of mortality by LTFU status in a high-resource setting. METHODS: Rates of LTFU were measured in the Australian HIV Observational Database for a range of patient characteristics. Multivariate repeated measures regression methods were used to identify determinants of LTFU. Mortality by LTFU status was ascertained using linkage to the National Death Index. Survival following combination antiretroviral therapy initiation was investigated using the Kaplan-Meier (KM) method and Cox proportional hazards models. RESULTS: Of 3,413 patients included in this analysis, 1,632 (47.8%) had at least one episode of LTFU after enrolment. Multivariate predictors of LTFU included viral load (VL)>10,000 copies/ml (rate ratio [RR] 1.63; 95% CI 1.45, 1.84; ref ≤400), time under follow-up (per year; RR 1.03; 95% CI 1.02, 1.04) and prior LTFU (per episode; RR 1.15; 95% CI 1.06, 1.24). KM curves for survival were similar by LTFU status (P=0.484). LTFU was not associated with mortality in Cox proportional hazards models (univariate hazard ratio [HR] 0.93; 95% CI 0.69, 1.26) and multivariate HR 1.04 (95% CI 0.77, 1.43). CONCLUSIONS: Increased risk of LTFU was identified amongst patients with potentially higher infectiousness. We did not find significant mortality risk associated with LTFU. This is consistent with timely re-engagement with treatment, possibly via high levels of unreported linkage to other health-care providers.
BACKGROUND: Loss to follow-up (LTFU) in HIV-positive cohorts is an important surrogate for interrupted clinical care, which can potentially influence the assessment of HIV disease status and outcomes. After preliminary evaluation of LTFU rates and patient characteristics, we evaluated the risk of mortality by LTFU status in a high-resource setting. METHODS: Rates of LTFU were measured in the Australian HIV Observational Database for a range of patient characteristics. Multivariate repeated measures regression methods were used to identify determinants of LTFU. Mortality by LTFU status was ascertained using linkage to the National Death Index. Survival following combination antiretroviral therapy initiation was investigated using the Kaplan-Meier (KM) method and Cox proportional hazards models. RESULTS: Of 3,413 patients included in this analysis, 1,632 (47.8%) had at least one episode of LTFU after enrolment. Multivariate predictors of LTFU included viral load (VL)>10,000 copies/ml (rate ratio [RR] 1.63; 95% CI 1.45, 1.84; ref ≤400), time under follow-up (per year; RR 1.03; 95% CI 1.02, 1.04) and prior LTFU (per episode; RR 1.15; 95% CI 1.06, 1.24). KM curves for survival were similar by LTFU status (P=0.484). LTFU was not associated with mortality in Cox proportional hazards models (univariate hazard ratio [HR] 0.93; 95% CI 0.69, 1.26) and multivariate HR 1.04 (95% CI 0.77, 1.43). CONCLUSIONS: Increased risk of LTFU was identified amongst patients with potentially higher infectiousness. We did not find significant mortality risk associated with LTFU. This is consistent with timely re-engagement with treatment, possibly via high levels of unreported linkage to other health-care providers.
Authors: Michael A Horberg; Leo B Hurley; Michael J Silverberg; Daniel B Klein; Charles P Quesenberry; Michael J Mugavero Journal: AIDS Patient Care STDS Date: 2013-07-19 Impact factor: 5.078
Authors: B Lebouché; Y Yazdanpanah; Y Gérard; D Sissoko; F Ajana; I Alcaraz; P Boitte; B Cadoré; Y Mouton Journal: HIV Med Date: 2006-04 Impact factor: 3.180
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: Jessie K Edwards; Stephen R Cole; Daniel Westreich; Richard Moore; Christopher Mathews; Elvin Geng; Joseph J Eron; Michael J Mugavero Journal: PLoS One Date: 2014-07-10 Impact factor: 3.240
Authors: Awachana Jiamsakul; Azar Kariminia; Keri N Althoff; Carina Cesar; Claudia P Cortes; Mary-Ann Davies; Viet Chau Do; Brian Eley; John Gill; Nagalingeswaran Kumarasamy; Daisy Maria Machado; Richard Moore; Hans Prozesky; Elizabeth Zaniewski; Matthew Law Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Awachana Jiamsakul; Stephen J Kerr; Sasisopin Kiertiburanakul; Iskandar Azwa; Fujie Zhang; Romanee Chaiwarith; Wingwai Wong; Penh Sun Ly; Nagalingeswaran Kumarasamy; Rossana Ditangco; Sanjay Pujari; Evy Yunihastuti; Cuong Duy Do; Tuti Parwati Merati; Kinh Van Nguyen; Man Po Lee; Jun Yong Choi; Shinichi Oka; Pacharee Kantipong; Benedict L H Sim; Oon Tek Ng; Jeremy Ross; Matthew Law Journal: AIDS Care Date: 2018-07-18
Authors: Nicole L De La Mata; Mi-Young Ahn; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Nicolas Durier; Matthew G Law Journal: J Clin Epidemiol Date: 2016-10-19 Impact factor: 6.437
Authors: A Jiamsakul; S Kiertiburanakul; O T Ng; R Chaiwarith; W Wong; R Ditangco; K V Nguyen; A Avihingsanon; S Pujari; C D Do; M-P Lee; P S Ly; E Yunihastuti; N Kumarasamy; A Kamarulzaman; J Tanuma; F Zhang; J Y Choi; P Kantipong; Blh Sim; J Ross; M Law; T P Merati Journal: HIV Med Date: 2019-04-12 Impact factor: 3.180
Authors: Nicole L De La Mata; David A Cooper; Darren Russell; Don Smith; Ian Woolley; Maree O Sullivan; Stephen Wright; Matthew Law Journal: Sex Health Date: 2016-04-21 Impact factor: 2.706
Authors: C E Kendall; J Raboud; J Donelle; M Loutfy; S B Rourke; A Kroch; C Liddy; R Rosenes; A N Burchell Journal: HIV Med Date: 2018-11-26 Impact factor: 3.094
Authors: David J Templeton; Stephen T Wright; Hamish McManus; Chris Lawrence; Darren B Russell; Matthew G Law; Kathy Petoumenos Journal: BMC Infect Dis Date: 2015-08-12 Impact factor: 3.090